Avelumab and Merkel Cell Carcinoma: A Medical and Risk Narrative

From General Health to Occupational Exposure

The legacy of general health and science communication has long emphasized broad preventive measures and population-level risk factors, drawing from large-scale trials that inform public health guidelines. In this tradition, the recent Japanese randomized trial of low-dose aspirin in older adults with cardiovascular risk factors exemplifies how rigorous evidence shapes our understanding of everyday interventions. Such studies anchor discussions in familiar, widely applicable contexts—diet, lifestyle, and common medications—where causation is carefully parsed through controlled observation. Transitioning from this general health perspective to a more specialized occupational exposure concern requires a shift in focus. While population studies address universal risks, occupational settings often involve targeted, repeated exposure to specific agents, demanding a narrower lens. Here, the question of causation becomes particularly acute when evaluating therapeutic agents like Avelumab, a monoclonal antibody used in oncology. In the context of mass production—where workers may handle or be exposed to such biologics—the concern shifts from patient outcomes to potential occupational hazards. Specifically, does Avelumab exposure increase the risk of Merkel Cell Carcinoma among manufacturing personnel? This pivot reframes causation not as a population-wide inquiry but as a discrete, workplace-specific risk assessment, bridging from general health literacy to the precise scrutiny of occupational exposure pathways.

Causation Analysis: Does Avelumab Cause Merkel Cell Carcinoma?

The question of whether avelumab causes Merkel cell carcinoma (MCC) requires careful examination of the drug's pharmacology, clinical trial data, and reported adverse events. Based on the available evidence, avelumab is not a cause of MCC; rather, it is an approved therapeutic agent for the treatment of metastatic MCC. The evidence consistently positions avelumab as a treatment for, not a trigger of, this malignancy. Merkel cell carcinoma is a rare, aggressive neuroendocrine cutaneous malignancy with a poor prognosis (https://pubmed.ncbi.nlm.nih.gov/33439294/). It is associated with chronic exposure to ultraviolet light and the Merkel cell polyoma virus, and the incidence rate is increasing (https://pubmed.ncbi.nlm.nih.gov/35877101/). MCC is characterized by high rates of recurrence and mortality (https://pubmed.ncbi.nlm.nih.gov/35877101/). Diagnosis typically involves histopathological examination and immunohistochemistry to confirm neuroendocrine differentiation.

Avelumab Pharmacology and Reported Adverse Effects

Avelumab (Bavencio®) is a fully human IgG1 monoclonal antibody directed against programmed cell death ligand 1 (PD-L1) (https://pubmed.ncbi.nlm.nih.gov/29799096/). It functions as an immune checkpoint inhibitor, blocking the PD-L1/PD-1 interaction to enhance anti-tumor immune responses. Avelumab has been approved in the USA, the EU, and Japan for the treatment of metastatic MCC, independent of line of treatment (https://pubmed.ncbi.nlm.nih.gov/29799096/). Approval was based on the JAVELIN Merkel 200 phase II trial, where confirmed objective responses were observed in approximately one-third of patients with chemotherapy-refractory metastatic MCC (https://pubmed.ncbi.nlm.nih.gov/29799096/). Reported adverse effects of avelumab include immune-related adverse events (irAEs) due to overactivation of the immune system (https://pubmed.ncbi.nlm.nih.gov/31543781/). For example, a case of hypercalcaemia secondary to reactivation of sarcoidosis during avelumab treatment for metastatic MCC has been documented, which was managed with corticosteroids and allowed continuation of avelumab therapy (https://pubmed.ncbi.nlm.nih.gov/31543781/). However, no evidence in the provided snippets suggests that avelumab causes MCC. Instead, the drug is used to treat MCC, and adverse events are typically immune-mediated rather than oncogenic.

Mechanistic Pathways Linking Avelumab to Merkel Cell Carcinoma

The evidence does not support a mechanistic pathway by which avelumab causes MCC. Immune checkpoint inhibitors, including avelumab, are known to improve treatment outcomes in metastatic MCC, with response rates to PD-1/PD-L1 inhibition of up to 62% (https://pubmed.ncbi.nlm.nih.gov/36450381/). Avelumab is specifically approved for MCC treatment, and its mechanism of action—blocking PD-L1—is intended to enhance the immune system's ability to attack cancer cells, not to induce new malignancies. The evidence indicates that avelumab is used in patients who already have MCC, and it is not implicated in the initiation of the disease.

Risk Anchors: Adequacy of Warnings, Causation Considerations, and Timeline

The evidence does not indicate that warnings about avelumab causing MCC are necessary, as the drug is not a causative agent. Instead, warnings focus on immune-related adverse events, such as sarcoidosis reactivation (https://pubmed.ncbi.nlm.nih.gov/31543781/). The prescribing information for avelumab likely includes standard warnings for immune checkpoint inhibitors, but no evidence suggests that MCC is listed as a potential adverse effect. Given that avelumab is approved for MCC treatment, warnings about causing the disease would be contradictory and unsupported by data. For patients with MCC, the question of causation is irrelevant because avelumab is a treatment, not a cause. Patients who develop MCC have the disease prior to avelumab exposure. The evidence shows that avelumab is used in patients with metastatic MCC, including those who are chemotherapy-refractory (https://pubmed.ncbi.nlm.nih.gov/29799096/). For patients who progress on avelumab, alternative treatments such as ipilimumab plus nivolumab have been studied (https://pubmed.ncbi.nlm.nih.gov/33439294/; https://pubmed.ncbi.nlm.nih.gov/36450381/; https://pubmed.ncbi.nlm.nih.gov/35877101/). These studies describe avelumab-refractory MCC, meaning the disease did not respond to avelumab, but this does not imply causation. The timeline between avelumab exposure and harm is relevant only for adverse events, not for MCC causation. For example, hypercalcaemia due to sarcoidosis reactivation occurred during avelumab treatment and was managed with corticosteroids (https://pubmed.ncbi.nlm.nih.gov/31543781/). In the JAVELIN Merkel 200 trial, responses were observed in approximately one-third of patients, indicating that harm (disease progression) is more likely in non-responders, but this is a lack of efficacy, not a causal link (https://pubmed.ncbi.nlm.nih.gov/29799096/). The evidence does not provide a timeline for MCC development after avelumab exposure because such a relationship does not exist.

Conclusion

Based on the provided evidence, avelumab does not cause Merkel cell carcinoma. Instead, it is an approved and effective treatment for metastatic MCC. The drug's pharmacology, clinical trial data, and reported adverse events all support its role as a therapeutic agent, not a causative factor. Warnings about avelumab focus on immune-related adverse events, and no evidence suggests that MCC should be listed as a potential harm. For affected patients, the primary consideration is treatment efficacy and management of adverse events, not causation.

Important Notice

This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.

Frequently Asked Questions

Does Avelumab cause Merkel Cell Carcinoma?

No, based on available evidence, Avelumab does not cause Merkel Cell Carcinoma (MCC). It is an approved treatment for metastatic MCC, and its mechanism of action is to enhance the immune system against cancer cells, not to induce new malignancies.

What are the adverse effects of Avelumab?

Avelumab can cause immune-related adverse events (irAEs) due to immune system overactivation, such as sarcoidosis reactivation leading to hypercalcaemia (https://pubmed.ncbi.nlm.nih.gov/31543781/). These are managed with corticosteroids and do not include causing MCC.

Does submitting information create an attorney-client relationship?

No. Submission requests an initial records screening only and does not create an attorney-client relationship.

Information Registry: individuals with documented Avelumab exposure and a confirmed Merkel Cell Carcinoma diagnosis may request an independent eligibility review. [Begin Assessment]

References

Request a Free Case Review

This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.